HIV Drug Resistance: The 4th Decade

HIV Drug Resistance: The 4th Decade

Presenters

Douglas D. Richman, MD
University of California San Diego and Veterans Affairs San Diego Healthcare System

Start

December 8, 2020 - 11:00 AM

End

December 8, 2020 - 12:15 PM

Add to iCal Calendar

Overview

Assessment of Needs

The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians.

Antiretroviral therapy has dramatically reduced the morbidity and mortality associated with HIV infection. The emergence of drug resistance had limited the effectiveness of many initial drugs, however drug resistance is more uncommon with contemporary regimens such as those that include integrase strand transfer inhibitors. Despite the diminished impact clinically, drug resistance is one of the most frequently requested topics for discussion by our audience. This webinar will provide an up-to-date review on drug resistance and how resistance impacts clinical care.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe up-to-date information on drug resistance
  • Describe how drug resistance impacts clinical care

Registration

Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, December 7, 2020, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

This activity is eligible for ANCC credit; see the final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoThis activity is eligible for ACPE credit; see the final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.